For all media queries please contact our Communications Advisor.
Medicines New Zealand believes that strong intellectual property protections are necessary for the discovery and development of new treatments and therapies for New Zealand patients, including innovative biologic medicines.
Medicines New Zealand believes signing of the TPP has potential to boost the New Zealand economy by between $2-4 billion per year, open up new markets for our exporters, and allow New Zealanders improved access to innovative and beneficial goods including medicines and vaccines.
Medicines New Zealand’s 2015 Value of Medicines Award was presented to Amy Chan, a doctoral candidate at the University of Auckland, last night at the organisation’s annual Parliamentary Dinner.
Dr Catherine Mohr, a global expert on robotic surgery and other innovative health solutions, will be in New Zealand for four days as the guest of Medicines New Zealand.
Dr Swee Tan, the Founder and Executive Director of the Gillies McIndoe Research Institute (GMRI), has continued the remarkable work that saw him win the Value of Medicines Award in 2014, funded by Medicines New Zealand. Applications for the 2015 Medicines New Zealand Value of Medicines Award are currently open.